# Dose Escalation and Expansion Study of CPO102, an Anti-claudin 18.2 ADC in Patients With Advanced Cancers

> **NCT05043987** · PHASE1 · WITHDRAWN · sponsor: **Conjupro Biotherapeutics, Inc.**

## Conditions studied

- Pancreatic Cancer
- Gastric Cancer

## Interventions

- **DRUG:** CPO102

## Key facts

- **NCT ID:** NCT05043987
- **Lead sponsor:** Conjupro Biotherapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-11-16
- **Primary completion:** 2022-11-16
- **Final completion:** 2022-11-16
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** New IND sponsor to initiate a separate study
- **Last updated:** 2023-09-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05043987

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05043987, "Dose Escalation and Expansion Study of CPO102, an Anti-claudin 18.2 ADC in Patients With Advanced Cancers". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05043987. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*